Rapid activation of haemostasis after hormonal emergency contraception

Thrombosis and Haemostasis

Volumn 97, Issue 1, 2007, Pages 15-20

  van Rooijen, Marianne ^a   Silveira, Angela ^a   Thomassen, Stella ^b   Hansson, Lars Olof ^c   Rosing, Jan ^b   Hamsten, Anders ^a   Bremme, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

APC resistance; Estrogen; Levonorgestrel; SHBG

Indexed keywords

APC PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; ETHINYLESTRADIOL; FIBRINOGEN; GESTAGEN; LEVONORGESTREL; NORGESTREL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; PROTHROMBIN; SEX HORMONE BINDING PROTEIN; THIETHYLPERAZINE MALEATE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; EMERGENCY CONTRACEPTION; FEMALE; HOMEOSTASIS; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RISK ASSESSMENT; SIDE EFFECT; THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ACTIVATED PROTEIN C RESISTANCE; ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD COAGULATION; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL; LIVER;

EID: 33846944343     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-09-0540     Document Type: Article

References (33)

1. Yuzpe AA, Lancee WJ. Ethinylestradiol and dl-norgestrel as postcoital contraceptive. Fertil Steril 1977; 28: 932-6.
2. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352: 428-33.
3. Lake SR, Vernon SA. Emergency contraception and retinal vein thrombosis. Br J Ophthalmol 1999; 83: 628.
4. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83.
5. Leiden mutation: A randomized trial. Blood 2004; 103: 927-33.
6. van Rooijen M, Silveira A, Hamsten A, et al. Sex hormone binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004; 190: 332-7.
7. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
8. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
9. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
10. Kaibara M, Watanabe T, Ooka F, et al. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer. Clin Hemorheol Microcirc 2001; 24: 93-9.
11. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1.
12. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70: 437-41.
13. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006; 259: 493-519.
14. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
15. Nicolaes GA, Thomassen MC, Tans G, et al. Effect of activated protein C on thrombin generation and on the thrombin potential in normal and AP-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
16. Kirk RE. Experimental design: Procedures for the behavioral sciences. Brooks/Cole Publishing Company Pacific Grove, USA 1995.
17. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models, Cary, NC: SAS Institute Inc., 1996.
18. Stege R, Carlstrom K, Collste L, et al. Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 1988; 11 (Suppl 2): S101-3.
19. Johansson E, Brache V, Alvarez F, et al. Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women. Human Reprod 2002; 17: 1472-6.
20. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165-9.
21. van Rooijen M, Hansson LO, Frostegard J, et al. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 4: 77-82.
22. Macintyre SS, Schultz D, Kushner I. Biosynthesis of C-reactive protein. Ann NY Acad Sci 1982; 389: 76-87.
23. Knopp RH, Broyles FE, Cheung M, et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63: 1-11.
24. Webb A, Taberner D. Clotting factors after emergency contraception. Adv Contracept 1993; 9: 75-82.
25. Weenink GH, Ten Cate JW, Kahlé LH, et al. "Morning after pill" and antithrombin III. Lancet 1981; 16: 1105.
26. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1-19.
27. Tholstrup T, Miller GJ, Bysted A, et al. Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clin Nutr 2003; 77: 1125-32.
28. de Visser MC, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-94.
29. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second and third generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
30. Curvers J, Thomassen MC, Nicholaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
31. Curvers J, Thomassen MC, Rimmer J, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Thromb Haemost 2002; 88: 5-11.
32. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, el at. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
33. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.